34841-11-7

Usage

Uses

Used in Organic Synthesis:
Methyl 2-methoxy-5-nitrobenzoate is used as a synthetic intermediate for the production of various organic compounds. Its unique structure allows it to be a versatile building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals. The presence of the nitro and methoxy groups on the benzene ring provides opportunities for further functionalization and modification, making it a valuable component in the development of new molecules with desired properties and applications.

InChI:InChI=1/C9H9NO5/c1-14-8-4-3-6(10(12)13)5-7(8)9(11)15-2/h3-5H,1-2H3

Upstream product

• 186581-53-3 diazomethane 
• 96-97-9 5-nitrosalicylic acid 
• 606-45-1 2-methoxybenzoic acid methyl ester 
• 103412-35-7 1-methoxy-12-norherbertene 
• 67-56-1 methanol 
• 90763-46-5 2-methoxy-5-nitrobenzoyl chloride 
• 74-88-4 methyl iodide 
• 17302-46-4 methyl 2-hydroxy-5-nitrobenzoate 
• 40751-89-1 2-methoxy-5-nitrobenzoic acid 
• 2516-96-3 2-chloro-5-nitrobenzoic acid 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 40751-89-1 2-methoxy-5-nitrobenzoic acid 
• 22802-67-1 methyl 2-methoxy-5-aminobenzoate 
• 885945-07-3 methyl 3-bromo-2-methoxy-5-nitrobenzoate 
• 920739-91-9 N-hydroxy-2-methoxy-5-nitrobenzamide 
• 34164-77-7 2-methoxy-5-nitrobenzoic acid hydrazide 
• 1569982-42-8 N-benzyl-2-methoxy-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)benzamide 
• 1569986-04-4 (4-methoxy-3-methoxycarbonyl-phenyl)-[6-(2-methoxy-phenyl)-pyrimidin-4-yl]-ammonium chloride 
• 1569982-45-1 (2-methoxy-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)phenyl)methanol 
• 1569982-47-3 2-methoxy-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)-N-methylbenzamide 
• 1569982-62-2 2-methoxy-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)-N-(pyridin-4-ylmethyl)benzamide 
• 1569982-66-6 2-methoxy-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)benzaldehyde 
• 1569982-68-8 methyl 2-methoxy-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)benzoate 
• 1569982-75-7 N-(3-((benzylamino)methyl)-4-methoxyphenyl)-6-(2-methoxyphenyl)pyrimidin-4-amine hydrochloride 
• 1569982-78-0 2-methoxy-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)benzohydrazide 

Relevant academic research and scientific papers

EIF4E INHIBITORS AND USES THEREOF

The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.

Aromatic β-sheet foldamers based on tertiary squaramides

The preference of N,N-aryl, alkyl tertiary amides for cis conformations has been exploited through the use of tertiary squaramides as hairpin turn units that promote the folding of aromatic β-sheets. Head-to-head aromatic arrangements were shown to prevail in sufficiently long bent aromatic sequences.

Folding and Assembly of Short α, β, ?-Hybrid Peptides: Minor Variations in Sequence and Drastic Differences in Higher-Level Structures

Multilevel protein structures typically involve polypeptides of sufficient lengths. Here we report the folding and assembly of seven short tetrapeptides sharing the same types of α-, β-, and aromatic ?-amino acid residues. These are two sets of hybrid peptides, with three members in one set and four in the other, having complementary hydrogen-bonding sequences that were hypothesized to pair into linear H-bonded duplexes. However, instead of undergoing the anticipated pairing, the initially examined three oligomers, 1 and 2a or 2b, differing only in their central αβ hybrid dipeptide sequence, do not associate with each other and exhibit distinctly different folding behavior. Experiments based on NMR and mass spectrometry, along with computational studies and systematic inference, reveal that oligomer 1 folds into an expanded β-turn containing an unusual hybrid α/β-amino acid sequence composed of glycine and β-alanine, two α- A nd β-amino acid residues that are conformationally most flexible, and peptides 2a and 2b adopt a noncanonical, extended helical conformation and dimerize into double helices undergoing rapid conformational exchange or helix inversion. The different central dipeptide sequences, αβ vs βα, result in drastically different intramolecular H-bonding patterns that are responsible for the observed folding behavior of 1 and 2. The revealed turn and double helix have few natural or synthetic counterparts, and provide novel and unique folding prototypes based on which chiral α- A nd β-amino acids are incorporated. The resultant derivatives 1a, 1b, 2c, and 2d follow the same folding and assembling behavior and demonstrate the generality of this system with the formation of expanded β-turns and double helices with enhanced folding stabilities, hampered helix inversion, as well as defined and dominant helical sense. This work has demonstrated the unique capability of synthetic foldamers in generating structures with fascinating folding and assembling behavior. The revealed systems offer ample opportunity for further structural optimization and applications.

NOVEL COMPOUNDS FOR USE IN CANCER

It relates to the compounds of formula (I), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures of stereoisomers, wherein X, L,R1, R 2, and R 3 are as defined herein, which are cancer cell differentiation inducing agents. It also relates to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of cancer, in particular by cell differentiation therapy.

One-Pot C?H Functionalization of Arenes by Diaryliodonium Salts

A transition-metal-free, mild, and highly regioselective synthesis of nitroarenes from arenes has been developed. The products are obtained in a sequential one-pot reaction by nitration of iodine(III) reagents with two carbon ligands, which are formed in situ from iodine(I). This novel concept has been extended to formation of aryl azides, and constitutes an important step towards catalytic reactions with these hypervalent iodine reagents. An efficient nitration of isolated diaryliodonium salts has also been developed, and the mechanism is proposed to proceed by a [2,2] ligand coupling pathway.

Compounds for use in treatment of mucostitis

The present invention provides methods for treating and/or preventing mucostitis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.

NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS

Certain 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents.

TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

Control over unfolding pathways by localizing photoisomerization events within heterosequence oligoazobenzene foldamers

From the inside out or from the outside in? Two photoswitchable foldamers that incorporate azobenzene moieties as the energy-acceptor units have been designed. The pathway of helix unfolding can be controlled by localizing these photoinduced triggers (sho

Design and Synthesis of Novel Cyclooxygenase-1 Inhibitors as Analgesics: 5-Amino-2-ethoxy-N-(substituted-phenyl)benzamides

We previously found that N-(4-aminophenyl)-4-trifluoromethylbenzamide (TFAP), a COX-1 inhibitor, exhibits an analgesic effect without causing gastric damage. Unfortunately, TFAP causes reddish purple coloration of urine, and its analgesic effect is less potent than that of indomethacin. Herein we describe our study focusing on the development of 4- and 5-amino-2-alkoxy-N-phenylbenzamide scaffolds, designed on the basis of the structures of TFAP and parsalmide, another known COX-1 inhibitory analgesic agent. 5-Amino-2-ethoxy-N-(2- or 3-substituted phenyl)benzamide derivatives exhibited analgesic activity in a murine acetic acid induced writhing test. Among these compounds, 5-amino-2-ethoxy-N-(2-methoxyphenyl)benzamide (9v) possesses potent COX-1 inhibitory and analgesic activities, similar to those of indomethacin. In addition, 5-amino-2-ethoxy-N-(3-trifluoromethylphenyl)benzamide (9g) showed a more potent analgesic effect than indomethacin or 9v without causing apparent gastric damage or coloration of urine, although its COX-1 inhibitory activity was weaker than that of indomethacin or 9v. Thus, 9g and 9v appear to be promising candidates for analgesic agents and are attractive lead compounds for further development of COX-1 inhibitors.